Pharmaceutical - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

176 to 200 of 311 results

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

GlaxoSmithKline and Theravance withdraw Japan NDA for Relvar Ellipta in COPD

12-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) revealed on Friday…

Asia-PacificBiotechnologyGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

US District Court issues final judgment in favor of Mylan in Brovana patent dispute

09-07-2013

US generics and specialty drugmaker Mylan (Nasdaq: MYL) revealed yesterday (July 8) that the US District…

BrovanaDainippon Sumitomo PharmaGenericsLegalMylan LaboratoriesNorth AmericaPatentsPerforomistPharmaceuticalRespiratory and PulmonarySunovion

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014

20-06-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

Teva to expand respiratory business with up to $165 million acquisition of MicroDose Therapeutx

18-06-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) has entered into a definitive agreement to acquire…

Mergers & AcquisitionsMicroDose TherapeutxPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Global asthma market to reach 159 million lifetime cases by 2022

16-06-2013

Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion.…

GlaxoSmithKlineGlobalMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySeretideSingulair

Zambon to acquire UK respiratory specialist Profile Pharma

10-06-2013

Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy…

Mergers & AcquisitionsPharmaceuticalProfile PharmaPromixinRare diseasesRespiratory and PulmonaryZambon

AstraZeneca to pay up to $1.15 billion to acquire Pearl Therapeutics

10-06-2013

In a further "strategic" bolt-on acquisition for Anglo-Swedish drug major AstraZeneca (LSE: AZN) in less…

AstraZenecaMergers & AcquisitionsPearl TherapeuticsPharmaceuticalPT003Respiratory and Pulmonary

Meda expands collaboration with India's Cipla on Dymista

06-06-2013

Swedish drugmaker Meda (OMX: MEDA A) is broadening its collaboration with Indian pharmaceutical company…

Asia-PacificCiplaDymistaLicensingMedaPharmaceuticalRespiratory and PulmonaryRest of the WorldSouth America

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort

30-05-2013

US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

US Appeals Court puts temporary stop on sales of generics of AstraZeneca's Pulmicort Respules

27-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last Friday (May 24) that the US Court of Appeals…

ActavisAstraZenecaGenericsLegalMarkets & MarketingNorth AmericaPharmaceuticalPulmicort RespulesRespiratory and Pulmonary

Grifols gains global rights to Aradigm's Pulmaquin

23-05-2013

Spanish drugmaker Grifols (GRLS: MC) has signed an exclusive, worldwide license for USA-based Aradigm's…

Antibiotics and Infectious diseasesAradigmCiprofloxacinGrifolsLicensingMergers & AcquisitionsPharmaceuticalPulmaquinRespiratory and Pulmonary

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

22-05-2013

French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN)…

BiotechnologydupilumabPharmaceuticalRegeneronResearchRespiratory and PulmonarySanofi

Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

17-05-2013

German family-owned drug major Boehringer Ingelheim said today (May 17) that it is updating health care…

Boehringer IngelheimCombivent RespimatManagementPharmaceuticalProductionRespiratory and Pulmonary

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Vectura sets up JV, Kinnovata, for new respiratory business in China

13-05-2013

UK-based developer of inhaled therapies Vectura (LSE: VEC) saw its shares rise 4.8% to 96.93 pence in…

Asia-PacificMergers & AcquisitionsPharmaceuticalProductionRespiratory and PulmonaryTianjin KingYorkTianjin Kinnovata PharmaVecturaZendex Bio Strategy

FDA approves Theravance and GSK's Breo Ellipta to treat COPD

13-05-2013

The US Food and Drug Administration on Friday (May 10) approved Breo Ellipta (fluticasone furoate, an…

BiotechnologyBreo ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySkyepharmaTheravance Biopharma

Mixed results for Almirall and Forest's LAMA/LABA combo for COPD

02-05-2013

Spain's largest drugmaker Almirall (ALM: MC) and US partner Forest Laboratories (NYSE: FRX) have announced…

aclidiniumAlmirallForest LaboratoriesformoterolPharmaceuticalResearchRespiratory and Pulmonary

GlaxoSmithKline files for umeclidinium monotherapy approval in Europe

29-04-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) has submitted a regulatory application in the European Union…

BiotechnologyEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceumeclidinium

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive new data on Novartis' once-daily QVA149 in COPD patients

23-04-2013

Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that Swiss…

NovartisPharmaceuticalQVA149ResearchRespiratory and Pulmonary

GlaxoSmithKline and Theravance file for Japanese approval of Anoro Ellipta

22-04-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) today April 22) announced…

Anoro ElliptaAsia-PacificGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

176 to 200 of 311 results

Back to top